OptimizeRx (OPRX) awards 34,517 restricted stock units to director Lang

Rhea-AI Filing Summary

Lang James Paul reported acquisition or exercise transactions in this Form 4 filing.

OptimizeRx Corp director James Paul Lang reported an equity award of 34,517 shares of common stock. The filing describes this as a grant of restricted stock units, representing a contingent right to receive shares of OptimizeRx common stock at no purchase price.

The restricted stock units will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. Following this award, Lang is reported as directly owning 433,837 shares of OptimizeRx common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lang James Paul

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	34,517	$0.00	--

Holdings After Transaction: Common Stock — 433,837 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 34,517 shares Award price per share: $0.0000 per share Shares held after transaction: 433,837 shares

3 metrics

RSUs granted 34,517 shares Restricted stock units granted on June 9, 2026

Award price per share $0.0000 per share Equity grant with no cash purchase price

Shares held after transaction 433,837 shares Common stock directly owned after the award

Key Terms

restricted stock units, contingent right to receive shares, annual meeting of shareholders

3 terms

restricted stock units financial

"Grant of restricted stock units representing a contingent right to receive shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right to receive shares financial

"restricted stock units representing a contingent right to receive shares of OptimizeRx common stock"

annual meeting of shareholders financial

"vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lang James Paul

(Last) (First) (Middle)

C/O OPTIMIZERX CORPORATION

260 CHARLES STREET, SUITE 302

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OptimizeRx Corp [ OPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		34,517(1)	A	$0	433,837	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person fi ling this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be fi led by such person.

	s/ Marion Odence-Ford, by Power of Attorney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OptimizeRx (OPRX) director James Paul Lang report?

James Paul Lang reported receiving 34,517 restricted stock units of OptimizeRx common stock as a grant. These units are a contingent right to receive shares and are characterized as a compensation-related award, not an open-market stock purchase or sale by the director.

How many OptimizeRx shares does James Paul Lang hold after this Form 4 transaction?

After the reported grant, James Paul Lang holds 433,837 shares of OptimizeRx common stock. This figure reflects his direct ownership position following the award of 34,517 restricted stock units disclosed in the Form 4 insider transaction filing.

What are the vesting terms for James Paul Lang’s 34,517 OptimizeRx restricted stock units?

The 34,517 restricted stock units will vest in full on the earlier of two dates. Vesting occurs on the first anniversary of the grant date or on the date of OptimizeRx’s next annual meeting of shareholders, whichever of those two events happens first.

Did James Paul Lang pay a purchase price for the OptimizeRx shares reported in this filing?

No cash purchase price was paid for these shares; the reported price per share is zero. The Form 4 characterizes the transaction as a grant or award, reflecting equity compensation provided by OptimizeRx rather than an open-market stock acquisition.

Is James Paul Lang’s Form 4 transaction in OptimizeRx stock a buy or sell in the market?

The transaction is reported as a grant or award acquisition, not a market buy or sell. It represents restricted stock units granted as equity compensation, which will convert into shares upon vesting based on the conditions described in the filing footnote.